Question 1

What is Priovant Therapeutics?

Accepted Answer

Priovant Therapeutics is a Entity.

Question 2

How often does Priovant Therapeutics appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 16 articles.

Question 3

When was Priovant Therapeutics first tracked by Ergen?

Accepted Answer

First tracked on Apr 02, 2026.

Question 4

When was Priovant Therapeutics last mentioned in news?

Accepted Answer

Last active on May 14, 2026.

Question 5

What is Priovant Therapeutics's current news sentiment?

Accepted Answer

Aggregate sentiment score: 20 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Priovant Therapeutics in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Priovant Therapeutics?

Accepted Answer

Roivant Brepocitinib Expansion, Immunovant Batoclimab Failure (Apr 02, 2026, 16 articles).

Question 8

How did the "Roivant Brepocitinib Expansion, Immunovant Batoclimab Failure" event impact Priovant Therapeutics?

Accepted Answer

Priovant Therapeutics, a subsidiary of Roivant Sciences, is expanding its brepocitinib development program into lichen planopilaris, which is a positive development for the company.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.